Bicalutamide Plus Everolimus May Be Effective for CRPC

The combination of bicalutamide and everolimus may be effective in men with bicalutamide-naïve castration-resistant prostate cancer.
The combination of bicalutamide and everolimus may be effective in men with bicalutamide-naïve castration-resistant prostate cancer.

The combination of bicalutamide and everolimus may be effective in men with bicalutamide-naïve castration-resistant prostate cancer (CRPC), a study published in the journal Cancer has shown.1

Although the mammalian target of rapamycin (mTOR) pathway is up-regulated in CRPC, inhibition of mTOR is not effective in inducing cell death of prostate cancer, possibly due to a compensatory up-regulation effect of the androgen receptor pathway.

Therefore, researchers sought to evaluate the combination of everolimus, an mTOR inhibitor, with bicalutamide, an oral antiandrogen.

For the phase 2 trial, researchers enrolled 24 patients with progressive CRPC who had not previously received bicalutamide (unless to prevent flare) or everolimus. Patients were only eligible if their serum testosterone level was less than 50 ng/dL.

Continue Reading Below

Patients enrolled had an average baseline prostate-specific antigen (PSA) level of 43 ng/dL and a median age of 71.1 years. All patients received bicalutamide 50 mg orally once daily and everolimus 10 mg orally once daily during each 4-week cycle. The average treatment length was 8 cycles.

Results showed that 75% (95% CI: 0.53-0.90) of the 24 patients achieved a PSA response and 62.5% (95% CI: 0.41-0.81) had a 50% or greater reduction in PSA.

Researchers found that median overall survival was 28 months (95% CI: 14.1-42.7).

In terms of safety, 54% (95% CI: 0.37-0.78) of patients developed grade 3 or 4 treatment-related adverse events and a substantial number of patients experienced everolimus-related toxicity.

REFERENCE

1. Chow H, Ghosh PM, deVere White R, et al. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer [published online ahead of print March 28, 2016]. Cancer. doi:10.1002/cncr.29927.
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs